<DOC>
	<DOCNO>NCT00347139</DOCNO>
	<brief_summary>In order obtain information wider range dose GW642444 ( possible new medication treat asthma ) previously examine asthmatic patient , current study conduct dos 25 100 400 mcg GW642444 compare salmeterol ( 50 mcg twice daily ) . This study conduct similar manner study already complete ( study number B2C101762 ) examine repeat dos 50 , 100 200 mcg GW642444 . The data obtain compliment data study B2C101762 provide confidence ( ) desire bronchodilation achieve maintain without undesirable side effect .</brief_summary>
	<brief_title>Repeat Doses Of A New Medication ( GW642444 ) In Asthmatic Patients</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Inclusion criterion : Subjects document history persistent asthma . Current nonsmoker . Clinically stable persistent asthma FEV1 60 90 % predicted value . Inhaled corticosteroid therapy total daily dose 200500mcg fluticasone equivalent . Exclusion criterion : Subjects significant past present disease may affect safety . Upper low respiratory tract infection within 4 week screen . History life threaten asthma , asthma require treatment oral corticosteroid within 3 month study . Patients take dos inhale corticosteroid &gt; 500mcg/day patient change therapy within 8 week study . Patients weigh less 50kg .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacodynamics</keyword>
	<keyword>Safety</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>GW642444</keyword>
	<keyword>Asthmatic patient</keyword>
	<keyword>Efficacy</keyword>
</DOC>